Document Detail

1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients.
Jump to Full Text
MedLine Citation:
PMID:  24505394     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: Elevated myocardial energy expenditure (MEE) is related with reduced left ventricular ejection fraction, and has also been documented as an independent predictor of cardiovascular mortality. However, the serum small-molecule metabolite profiles and pathophysiological mechanisms of elevated MEE in heart failure (HF) are still lacking. Herein, we used 1H-NMR-based metabolomics analysis to screen for potential biomarkers of MEE in HF.
METHODS: A total of 61 subjects were enrolled, including 46 patients with heart failure and 15 age-matched controls. Venous serum samples were collected from subjects after an 8-hour fast. An INOVA 600 MHz nuclear magnetic resonance spectrometer with Carr-Purcell-Melboom-Gill (CPMG) pulse sequence was employed for the metabolomics analysis and MEE was calculated using colored Doppler echocardiography. Metabolomics data were processed using orthogonal signal correction and regression analysis was performed using the partial least squares method.
RESULTS: The mean MEE levels of HF patients and controls were 139.61±58.18 cal/min and 61.09±23.54 cal/min, respectively. Serum metabolomics varied with MEE changed, and 3-hydroxybutyrate, acetone and succinate were significantly elevated with the increasing MEE. Importantly, these three metabolites were independent of administration of angiotensin converting enzyme inhibitor, β-receptor blockers, diuretics and statins (P>0.05).
CONCLUSIONS: These results suggested that in patients with heart failure, MEE elevation was associated with significant changes in serum metabolomics profiles, especially the concentration of 3-hydroxybutyrate, acetone and succinate. These compounds could be used as potential serum biomarkers to study myocardial energy mechanism in HF patients.
Zhiyong Du; Anna Shen; Yuli Huang; Liang Su; Wenyan Lai; Peng Wang; Zhibing Xie; Zhiquan Xie; Qingchun Zeng; Hao Ren; Dingli Xu
Related Documents :
2109924 - Effects of glyburide on ischemia-induced changes in extracellular potassium and local m...
3536094 - Silent myocardial ischemia and its relationship to acute myocardial infarction.
8298064 - Depressed adenosine and total purine catabolite production in the postischemic rat heart.
24118114 - Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin ve...
22733534 - Pet: is myocardial flow quantification a clinical reality?
18000024 - Is internal massage superior to external massage for patients suffering a cardiac arres...
Publication Detail:
Type:  Journal Article     Date:  2014-02-05
Journal Detail:
Title:  PloS one     Volume:  9     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2014  
Date Detail:
Created Date:  2014-02-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e88102     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2014 Du et al
Received Day: 2 Month: 11 Year: 2013
Accepted Day: 7 Month: 1 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 5 Month: 2 Year: 2014
Volume: 9 Issue: 2
E-location ID: e88102
PubMed Id: 24505394
ID: 3914925
Publisher Id: PONE-D-13-44927
DOI: 10.1371/journal.pone.0088102

1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients Alternate Title:Markers of MEE in HF
Zhiyong Du12
Anna Shen13
Yuli Huang1
Liang Su12
Wenyan Lai12
Peng Wang12
Zhibing Xie12
Zhiquan Xie4
Qingchun Zeng12
Hao Ren25*
Dingli Xu12*
Petras Dzejaedit1 Role: Editor
1Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2Key Laboratory For Organ Failure Research, Ministry of Education of the People's Republic of China, Guangzhou, China
3Department of Cardiology, The Third Hospital of Southern Medical University, Guangzhou, China
4Department of Cardiology, Guangzhou General Hospital of PLA, Guangzhou, China
5Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Mayo Clinic, United States of America
Correspondence: * E-mail: (HR); (DX)
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: DX ZD. Performed the experiments: AS LS ZD PW Zhibing Xie YH Zhiquan Xie. Analyzed the data: ZD YH LS. Contributed reagents/materials/analysis tools: WL PW Zhibing Xie HR. Wrote the paper: YH ZD AS QZ. Obtained funding: DX. Study supervision: DX HR.


Cardiac energy and metabolism are tightly regulated for a high and constant workload, however such regulation becomes compromised in heart failure [1], [2], [3]. It had been documented that elevated myocardial energy expenditure (MEE) is related with left ventricular ejection fraction (LVEF), as well as an independent predictor of cardiovascular mortality [4]. For this reason, significant efforts have been directed towards the pathophysiological mechanisms of elevated MEE. The conventional way to estimate MEE in the failing heart is to calculate the amount of O2 extracted by the left ventricle from arterial blood. However, this method is difficult and invasive. Some advanced imaging techniques, such as positron emission tomography, single-photon emission tomography and phosphorus-31 magnetic resonance (31P-MR) have allowed the non-invasive measurement of cardiac metabolism [5], [6]. Doppler echocardiography has been employed to estimate MEE by integrating a number of physiological factors contributing to myocardial energetic requirement in addition to wall stress, i.e., stroke volume and left ventricle (LV) ejection time [7].

Metabolomic analysis, the systematic study of small-molecule metabolite profiles, has been used to identify potential biomarkers that provide new insights into biological processes [8]. Recently, studies have shown that there are significant metabolic differences in the serum [9], [10] and urine [11] samples between heart failure (HF) patients and the control subjects. This finding suggests that concentration of some serum metabolites may well correlate with MEE levels, the former of which could be conveniently monitored by metabolomic analysis methods such as 1H NMR spectroscopy. However, a metabolomic investigation of serum metabolites associated with different MEE levels in HF patients has not yet been reported. In the present study, we performed NMR-based metabolomic analysis on serum obtained from HF patients, in an effort to determine the serum metabolites differences of patients with different MEE levels.

Materials and Methods
Ethics statement

This study was carried out in accordance with the Helsinki Declaration. This study was approved by the institutional ethics committee of Nanfang Hospital. All subjects had provided their written informed consent to participate in this study.


For this study, 46 HF patients (Male: 35; Female: 11, aged 28–87 years, mean age 62.7±13.0 years) from the cardiology department of Nanfang Hospital were recruited. All patients were staged in NYHA (New York Heart Association) class II (n = 11), III (n = 18) and IV (n = 17). The exclusion criteria were: (1) type 2 diabetes mellitus and other metabolic disease; (2) acute or chronic inflammatory conditions; (3) malignancies, and (4) significant respiratory pathology. Fifteen age-matched controls with normal cardiac function (Male: 8; Female: 7, aged 30–80 years, mean age 57.8±10.8) were recruited from the health management center in Nanfang Hospital.

MEE measurement

MEE was measured with a Siemens Sequoia 512 Encompass ultrasound system, using the method described previously [4], [7], which assumed that (1) end-systolic stress is a representative measure of the systolic tension applied to the myocardium during the ejection phase, (2) Doppler echocardiography was permitted to estimate the mass moved by the myocardium, and (3) trans-aortic Doppler flow could be used to measure the period during LV ejection (LV ejection time, LVET). Finally, MEE was calculated as:

MEE (kcal/min)  = LV circumferential end-systolic wall stress (cESS) ×LVET×LV stroke volume (LVSV)×HR×4.2×10−4.

Sample collection

Venous blood was collected from the antecubital vein on the same day of MEE measurement, coagulated at room temperature for 10 min, and centrifuged at 3000 g at 4°C for 10 min. The resulting supernatant serum was collected and stored at −80°C.

Sample preparation and 1H-NMR spectroscopy

Stored serum samples were thawed prior to NMR analysis. 300 µl of serum was mixed with 200 µl D2O and 100 µl 3-trimethylsilyl-2H4-propionic acid sodium salt (TSP) in D2O (1 mg/ml). After centrifuged at 13000 g for 10 min, 550 µl aliquots of the supernatant were transferred into 5-mm NMR tubes for analysis.

1H-NMR spectra of the serum samples were acquired on a Varian INOVA 600 MHz spectrometer at 27°C using Carr-Purell-Meiboom-Gill (CPMG) spin-echo pulse sequence with a total spin-spin relaxation delay (2 nτ) of 320 ms. The free induction decays (FIDs) were collected into 32 k data points with a spectral width of 8000 Hz and 64 scans. The FIDs were zero-filled to double size and multiplied by an exponential line-broadening factor of 0.5 Hz prior to Fourier transformation (FT). All serum 1H-NMR spectra were manually phased and baseline corrected using VNMR 6.1C software (Varian Inc., Palo Alto, CA, USA). Each spectrum over the range of δ 0.4–4.4 was data-reduced into integrated regions of equal width (0.01 ppm). The regions containing the resonance from residual water (δ4.6–5.1) were removed. The integral values of each spectrum were normalized to a constant sum of all integrals in a spectrum. Identification of metabolites in spectra was accomplished based on information in the literature and the Chenomx NMR Suite 5.0 (Chenomx, Calgary, Canada).

Statistical analysis

Clinical, functional data and metabolite concentration are presented as mean ± SD or percentages as appropriate. All the included subjects were divided into three quartile groups according to MEE level. Differences between MEE groups were evaluated using the χ2 test for discrete clinical variables and by one-way ANOVA for continuous variables. Differences within groups were evaluated using the Bonferroni method if variables were equal; otherwise Dunnett's T3 test was used. The resulting integral NMR data were imported into SIMCA-P (version 11.5; Umetrics, Umeå, Sweden) for multivariate analysis. The CPMG data were mean-centered and Pareto-scaled prior to analysis. Principle component analysis was performed to observe the samples distribution. To remove the variations not correlated to the group membership, the data were preprocessed using orthogonal signal correction (OSC) followed by PLS analysis.

Baseline characteristics of variable MEE groups

The mean ejection fraction in HF patients was 39.59±10.94%, 48% showed mildly reduced EF (40%–54%), and 52% had severely reduced EF (≤40%). Medical treatment for the HF patients consisted of diuretics (71.7%), β-blockers (73.9%), angiotensin converting enzyme inhibitors or angiotensin II receptor blocker (69.6%), and statins (28.3%). The mean MEE levels of HF patients and controls were 139.61±58.18 cal/min and 61.09±23.54 cal/min, respectively. All the included subjects (46 HF patients and 15 controls) were divided into three quartile groups according to MEE level. Those with an MEE<72.53 cal/min were included in the low MEE group (Q1); 72.53≤MEE<176.75 cal/min in the intermediate MEE group (Q2+Q3); MEE≥176.75 cal/min in the high MEE group (Q4). Distribution of participants and baseline characteristics of the three groups are shown in Table 1. Participants in the high MEE group had higher NYHA classification than other groups (χ2 = 33.02, P<0.001). Those in the high MEE group had higher fasting glucose, very low density lipoprotein (VLDL), creatinine, uric acid, and BNP levels and a lower LVEF than those in the low MEE group.

1H-NMR spectroscopy of serum from different MEE groups

Representative standard 1D 600 MHz 1H-NMR spectra of serum from low, intermediate and high MEE groups groups showed a large numbers of NMR signals, which indicated the complexity of spectral information obtained from the patient donors (Fig. 1). Identification of metabolites in spectra was accomplished based on information in the literature and the 600 MHz library of the Chenomx NMR Suite 5.0 (Chenomx, Calgary, Canada). As noted in Fig. 1, major metabolites identified in serum included amino acids (valine, alanine, glutamine, methionine, glycine), organic acid (3-hydroxybutyrate, lactate, acetone, succinate, creatine), low-density lipoprotein (LDL) and VLDL, glucose, choline and phosphocholine, N-Acetyl glycoprotein, and trimethylamine-N-oxide.

Metabolomics analysis of serum from variable MEE groups

Initially, principal components analysis was applied to examine the intrinsic variation in the serum of all MEE level groups. As shown in Fig. 2, a slight discrimination was observed between all MEE groups by the scores plots of PC1 versus PC2 (R2 = 0.694, Q2 = 0.347). Pairwise PCA score plots showed a significant difference between the high and low MEE groups by the score plots of PC1 versus PC2 (R2 = 0.649, Q2 = 0.091) (Fig. 3), but no separation among the low MEE, high MEE and intermediate MEE in serum, respectively. PLS was used to find differential metabolites between groups. Two-dimensional scores plots are shown in Figure S1S3. Next, the data were preprocessed using orthogonal signal correction (OSC) to remove the variations not correlated to the group membership and to further improve the separation among the three groups[12], [13]. OSC-PLS score plots are shown in Fig. 4; all three groups were located in different clusters (R2Y = 92.6% and Q2Y = 90.2%). OSC-PLS cross validating parameter are shown in Table 2. Pairwise OSC-PLS also showed discrimination between the groups. Subsequently, this OSC-PLS model was validated with the permutation testing, when Y was randomly permuted 100 times. By comparing R2Y and Q2Y values of the original model with those of the re-ordered models this type of permutation gauges the statistical significance of the predicting power of the models. It is known that models with a R2Y intercept less than 0.3 and a Q2Y intercept less than 0.05 indicate valid models [14]. In our study, the permutation test plot showed a proper R2Y (∼0.24) and Q2Y (−0.29) intercept values, which suggested the validity of our OSC-PLS model (Fig. 5). In the SIMCA-P software, the contribution size of variables in the OSC-PLS model was usually expressed as the value of variable importance in projection (VIP). VIP values and correlation coefficients were shown in the V-plot (Fig. 6). Variables in both terminals of “V” represented a high contribution to size and reliability. Variables were screened according to the VIP value (>1) and 49 potential differential variables were selected. Finally, a total of 18 metabolites were identified according to literature [15], [16] and the HMDB database (Table 3).

To validate whether the identified metabolites varied with different MEE levels, metabolites were compared among groups using the one-way ANOVA method (Table 4). It was found that concentration of serum 3-Hydroxybutyrate, acetone and succinate were increased with the increasing of MEE (Table 3, Fig. 7). Importantly, these three metabolites were independent of administration of angiotensin converting enzyme inhibitor, β-receptor blockers, diuretics and statins (P>0.05). In addition, the differences of LDL, VLDL, lactate, N-acetyl glycoprotein, choline, phosphocholine, α-glucose, β-glucose, trimethylamine-N-oxide and glycine were not significant among the three groups. Taking the diagnostic criteria of the Framingham Heart Study (FHS) as the benchmark, receiver operating curves (ROCs) of acetone, 3-hydroxybutyrate, succinate and BNP for diagnosis of HF were compared. These results indicated areas under the curve (AUC) were 0.92, 0.90, 0.86 and 0.98, respectively (Fig. 8).


Cardiac energy metabolism is strongly related to oxygen supply [17], [18]. MEE has been one of the major indices of myocardial energy metabolism. This study found significant differences in serum metabolic groups between HF patients with different MEE, and screening of these metabolites identified three important serum markers that reflect the myocardial energy metabolism. Our findings thus increase the knowledge of human myocardial metabolism changes in heart failure.

MEE derived from standard echocardiographic measurements is an effective indicator for myocardial bioenergetics and significantly correlated with cardiac function in chronic HF patients, particularly in chronic HF patients with reduced LVEF [4], [19], [20]. Elevated level of MEE and lower adipose mass had been reported to be more effectively to predict cardiac death than EF [4]. In a previous study, our group also showed that in patients with HF after acute myocardial infarction, 12-month treatment with higher doses perindopril can improved myocardial remodeling and left ventricular systolic function, and decreased MEE [21]. These data showed that MEE is important for prognosis of patients with HF.

In the current study, 61 subjects were divided into three groups based on MEE levels. Serum metabolism profiles of these three groups were analyzed via model-identifying methods such as PCA and OSC-PLS. It was observed that OSC-PLS could effectively distinguish the features in different MEE groups, especially for high- and low-MEE groups. Moreover, according to the VIP value and one-way ANOVA results, three metabolites (3-hydroxybutyrate, acetone and succinate) were shown to rise with increasing MEE. Furthermore, the association of these three metabolites with MEE was independent of all treatment regimes including angiotensin converting enzyme inhibitor, β-receptor blockers, diuretics and statins. Both 3-hydroxybutyrate and acetone are ketone bodies, and mainly synthesized from oxidation of fatty acid catalyzed by acetylcoenzyme A in the liver. In general, myocardial energy acquisition via ketones oxidation pathways is dependent on the concentration. When the ketone bodies level is very low in the serum, they only provide a very small part of the energy required by the myocardium. However, in hungry or diabetes mellitus patients, blood ketone bodies level are greatly increased due to low insulin and high fatty acid levels, and they becomes the major energy supplier of the myocardium [22], [23]. It has been found by Lommi et al[24], [25]. that ketone bodies levels were significantly higher in patients with chronic HF than the normal population, possibly due to neuroendocrine hormone activation. In this study, we found that 3-hydroxybutyrate and acetone levels were significant increased in HF patients, which is consistent with the above results. More importantly, we found that these ketone bodies level were significantly associated with increasing myocardial energy consumption. Some studies have reported that oxidation and utilization of ketone bodies could inhibit the oxidation of fatty acids by the myocardium [26], [27]. Hence, increase of ketone bodies can promote the conversion of myocardial energy consumption from adult myocardium substrate (i.e., fatty acids) to the embryonal myocardium substrate in HF. Although the mechanism of ketone bodies inhibiting fatty acid metabolism remains unclear, it is inferred to correlate with increasing NADH/NAD+ ratio in the mitochondria, following ketone body utilization to inhibit β-oxidation of fatty acids [28], [29]. Taken these data together, the change of ketone bodies levels may play an important role in pathophysiological mechanisms of elevated MEE in HF.

Succinate is not only an important intermediate metabolite in the tricarboxylic acid cycle but also an important component of the electron respiratory chain complex II. In our study, the succinate level in the high-MEE group was increased by 1.4-fold compared with the intermediate-MEE group, which was a further 2.4-fold higher than the low-MEE group, suggesting that succinate is closely related to myocardial energy metabolism. Pisarenko et al[30]. observed that ATP and phosphocreatine levels significantly decreased in the isolated heart, and succinate level was significantly increased in the myocardial perfusate early following reperfusion of the Guinea pig model. Furthermore, succinate also decreased to a normal level together with ATP and phosphocreatine after 30 min. To summarize, these results suggest that succinate level is a marker of myocardial energy. Succinate dehydrogenase is not only the sole enzyme binding mitochondrial inner membrane but also the key enzyme in the tricarboxylic acid cycle, responsible for catalysis from succinic acid to fumaric acid. So the lack of succinic dehydrogenase can cause dilated cardiomyopathy and even HF [31]. It is refered that decreasing activity or suppressed expression of succinate dehydrogenase may be one of the mechanisms for energy production disorder in HF, and as a result, may also induce accumulation of upstream intermediate metabolite succinate, causing elevation of succinate level in the peripheral blood.


Significant differences were found among serum metabolic groups of different MEE in HF patients, and three serum markers (3-hydroxybutyrate, acetone and succinate) were identified to reflect the myocardial energy metabolism in elevated MEE by using 1H NMR-based metabolic analysis. More advanced technique, such as utility of both 1D noesy and cpmg spectra, may be carried out in future studies to reaffirm the identified metabolites. If these results are confirmed, more studies are needed to investigate the pathophysiological mechanism that dictates elevated levels of these metabolites with increasing MEE in chronic HF.

Supporting Information Figure S1

PLS score plot of three MEE groups.


Click here for additional data file (pone.0088102.s001.doc)

Figure S2

PLS score plot of low MEE and intermediate MEE.


Click here for additional data file (pone.0088102.s002.doc)

Figure S3

PLS score plot of low MEE and high MEE.


Click here for additional data file (pone.0088102.s003.doc)

We thank the patient donors and the supporting medical staff for making this study possible.

1. van Bilsen M,, van Nieuwenhoven FA,, van der Vusse GJ, (Year: 2009) Metabolic remodelling of the failing heart: beneficial or detrimental?Cardiovasc Res81: 420–42818854380
2. Neubauer S, (Year: 2007) The failing heart–an engine out of fuel. N Engl J Med356: 1140–115117360992
3. Mudd JO,, Kass DA, (Year: 2008) Tackling heart failure in the twenty-first century. Nature451: 919–92818288181
4. Palmieri V,, Roman MJ,, Bella JN,, Liu JE,, Best LG,, et al. (Year: 2008) Prognostic implications of relations of left ventricular systolic dysfunction with body composition and myocardial energy expenditure: the Strong Heart Study. J Am Soc Echocardiogr21: 66–7117628407
5. Shah SH,, Kraus WE,, Newgard CB, (Year: 2012) Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation126: 1110–112022927473
6. Rhee EP,, Gerszten RE, (Year: 2012) Metabolomics and cardiovascular biomarker discovery. Clin Chem58: 139–14722110018
7. Kaddurah-Daouk R,, Krishnan KR, (Year: 2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology34: 173–18618843269
8. O'Hagan S,, Dunn WB,, Knowles JD,, Broadhurst D,, Williams R,, et al. (Year: 2007) Closed-loop, multiobjective optimization of two-dimensional gas chromatography/mass spectrometry for serum metabolomics. Anal Chem79: 464–47617222009
9. Kang SM,, Park JC,, Shin MJ,, Lee H,, Oh J,, et al. (Year: 2011) (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem44: 293–29921167146
10. Tenori L,, Hu X,, Pantaleo P,, Alterini B,, Castelli G,, et al. (Year: 2013) Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol168: e113–13524007967
11. Palmieri V,, Bella JN,, Arnett DK,, Oberman A,, Kitzman DW,, et al. (Year: 2003) Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study. Am Heart J145: 1071–107712796765
12. Beckwith-Hall BM,, Brindle JT,, Barton RH,, Coen M,, Holmes E,, et al. (Year: 2002) Application of orthogonal signal correction to minimise the effects of physical and biological variation in high resolution 1H NMR spectra of biofluids. Analyst127: 1283–128812430596
13. Gavaghan CL,, Wilson ID,, Nicholson JK, (Year: 2002) Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. FEBS letters530: 191–19612387891
14. Kim SH,, Yang SO,, Kim HS,, Kim Y,, Park T,, et al. (Year: 2009) 1H-nuclear magnetic resonance spectroscopy-based metabolic assessment in a rat model of obesity induced by a high-fat diet. Anal Bioanal Chem395: 1117–112419711056
15. Nicholson JK,, Foxall PJ,, Spraul M,, Farrant RD,, Lindon JC, (Year: 1995) 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem67: 793–8117762816
16. Foxall PJ,, Parkinson JA,, Sadler IH,, Lindon JC,, Nicholson JK, (Year: 1993) Analysis of biological fluids using 600 MHz proton NMR spectroscopy: application of homonuclear two-dimensional J-resolved spectroscopy to urine and blood plasma for spectral simplification and assignment. J Pharm Biomed Anal11: 21–318466956
17. Turer AT,, Stevens RD,, Bain JR,, Muehlbauer MJ,, van der Westhuizen J,, et al. (Year: 2009) Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation119: 1736–174619307475
18. Nagoshi T,, Yoshimura M,, Rosano GM,, Lopaschuk GD,, Mochizuki S, (Year: 2011) Optimization of cardiac metabolism in heart failure. Curr Pharm Des17: 3846–385321933140
19. Aquilani R,, Opasich C,, Verri M,, Boschi F,, Febo O,, et al. (Year: 2003) Is nutritional intake adequate in chronic heart failure patients?J Am Coll Cardiol42: 1218–122314522484
20. Shen AN,, Du ZY,, Wang P,, Xie ZB,, Xu DL, (Year: 2010) [Value of Doppler echocardiography derived myocardial energy expenditure measurements in chronic heart failure patients]. Zhonghua Xin Xue Guan Bing Za Zhi38: 209–21420450561
21. Liang J, Bai S, Xu D, Cheng Z (2012) [Effect of different doses of perindopril on myocardial energy expenditure in patients with heart failure following myocardial infarction]. Nan Fang Yi Ke Da Xue Xue Bao 32: : 1816–1819, 1832.
22. Avogaro A,, Nosadini R,, Doria A,, Fioretto P,, Velussi M,, et al. (Year: 1990) Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol258: E606–E6182333960
23. Hall JL,, Stanley WC,, Lopaschuk GD,, Wisneski JA,, Pizzurro RD,, et al. (Year: 1996) Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol271: H2320–H23298997289
24. Lommi J,, Kupari M,, Koskinen P,, Naveri H,, Leinonen H,, et al. (Year: 1996) Blood ketone bodies in congestive heart failure. J Am Coll Cardiol28: 665–6728772754
25. Lommi J,, Koskinen P,, Naveri H,, Harkonen M,, Kupari M, (Year: 1997) Heart failure ketosis. J Intern Med242: 231–2389350168
26. Forsey RG,, Reid K,, Brosnan JT, (Year: 1987) Competition between fatty acids and carbohydrate or ketone bodies as metabolic fuels for the isolated perfused heart. Can J Physiol Pharmacol65: 401–4063107785
27. Chen V,, Wagner G,, Spitzer JJ, (Year: 1984) Regulation of substrate oxidation in isolated myocardial cells by beta-hydroxybutyrate. Horm Metab Res16: 243–2476735347
28. Kerbey AL,, Randle PJ,, Cooper RH,, Whitehouse S,, Pask HT,, et al. (Year: 1976) Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetyl-coenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J154: 327–348180974
29. Kunau WH,, Dommes V,, Schulz H, (Year: 1995) beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog Lipid Res34: 267–3428685242
30. Pisarenko O,, Studneva I,, Khlopkov V, (Year: 1987) Metabolism of the tricarboxylic acid cycle intermediates and related amino acids in ischemic guinea pig heart. Biomed Biochim Acta46: S568–S5712893608
31. Davili Z,, Johar S,, Hughes C,, Kveselis D,, Hoo J, (Year: 2007) Succinate dehydrogenase deficiency associated with dilated cardiomyopathy and ventricular noncompaction. Eur J Pediatr166: 867–87017082968


[Figure ID: pone-0088102-g001]
doi: 10.1371/journal.pone.0088102.g001.
Figure 1  Representative 6001H-NMR spectra of serum from low, intermediate and high MEE groups, showing the structural complexity produced by multiple metabolite signals.

[Figure ID: pone-0088102-g002]
doi: 10.1371/journal.pone.0088102.g002.
Figure 2  Principal component analysis (PCA) scores plot from low, intermediate and high MEE groups.

[Figure ID: pone-0088102-g003]
doi: 10.1371/journal.pone.0088102.g003.
Figure 3  Principal component analysis (PCA) score plot between the low and high MEE groups.

[Figure ID: pone-0088102-g004]
doi: 10.1371/journal.pone.0088102.g004.
Figure 4  First two components of the OSC-PLS model scores for serum data of low, intermediate and high MEE groups.

[Figure ID: pone-0088102-g005]
doi: 10.1371/journal.pone.0088102.g005.
Figure 5  OSC-PLS model validation plot of low, intermediate and high MEE groups.

[Figure ID: pone-0088102-g006]
doi: 10.1371/journal.pone.0088102.g006.
Figure 6  OPLS model V plot of low, intermediate and high MEE groups.

[Figure ID: pone-0088102-g007]
doi: 10.1371/journal.pone.0088102.g007.
Figure 7  3-hydroxybutyrate, acetone and succinate level in the three MEE groups.

* p<0.05 vs. Low MEE.

[Figure ID: pone-0088102-g008]
doi: 10.1371/journal.pone.0088102.g008.
Figure 8  ROC of acetone, 3-hydroxybutyrate, succinate and BNP for CHF.

[TableWrap ID: pone-0088102-t001] doi: 10.1371/journal.pone.0088102.t001.
Table 1  Demographic and clinical characteristics of patients in different-MEE groups.
Low MEE Intermediate MEE High MEE P value
(n = 15) (n = 31) (n = 15)
Participants' distribution <0.001
Healthy 10(66.7%) 5(16.1%) 0
NYHA II 2(13.3%) 9(29.0%) 0
NYHA III 2(13.3%) 6(19.4%) 10(66.7%)
NYHA IV 1(6.7%) 11(35.5%) 5(33.3%)
Age (years) 58.67±10.59 61.29±13.57 64.93±12.56 NS
Sex (Male/Female) 8/7 23/8 12/3 NS
BMI (kg/m2) 23.23±2.46 23.48±2.94 23.19±2.62 NS
Fasting glucose (mg/dl) 85.41±18.92 85.41±11.89 96.95±12.43Δ§ <0.05
Triglyceride (mg/dl) 167.35±123.96 127.50±62.87 116.88±46.93 NS
Total cholesterol (mg/dl) 181.36±56.46 155.07±46.40 167.05±42.54 NS
HDL-cholesterol (mg/dl) 43.70±13.92 39.83±15.47 37.12±11.60 NS
LDL-cholesterol (mg/dl) 87.79±27.84 91.26±34.03 100.16±38.67 NS
VLDL-cholesterol (mg/dl) 48.72±24.75 32.49±16.63 34.80±13.15Δ <0.05
Creatinine (mg/dl) 0.87±0.34 1.15±0.36Δ 1.38±0.56Δ <0.01
eGFR (ml/min·1.73 m2) 60.36±18.71 55.40±16.48 52.05±22.91 NS
Uric acid (mg/dl) 6.07±2.48 8.30±2.47Δ 9.39±2.76Δ <0.01
NT-proBNP (pg/ml) 152±2143 2265±3177 4773±5255 ----
Log NT-proBNP 2.32±0.71 3.22±0.70Δ 3.59±0.49Δ <0.01
CRP (mg/dl) 0.55±0.63 0.96±0.75 1.73±1.13Δ§ <0.01
LVEF (%) 58±12 46±14 32±6 <0.01
ACEI/ARB 3(20%) 17(54.8%) 12(80%) <0.05
β-Blockers 3(20%) 18(58.1%) 13(86.7%) <0.05
Diuretics 3(20%) 17(54.8%) 13(86.7%) <0.05
Statins 0 8(25.8%) 5(33.3%) 0.057

Δvs low MEE P<0.05, §vs intermediate MEE P<0.05.

MEE: myocardial energy expenditure; BMI: body mass index; HDL: high densitv lipoprotein; LDL: low-density lipoprotein; VLDL: very low density lipoprotein; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro brain natriuretic peptide; CRP: c-reactive protein; LVEF: left ventricular ejection fraction; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.

[TableWrap ID: pone-0088102-t002] doi: 10.1371/journal.pone.0088102.t002.
Table 2  OSC-PLS cross validating parameter between different-MEE groups.
Numbers R2X R2Y Q2Y
3 Groups 2 0.386 0.926 0.902
Low MEE vs Intermediate MEE 2 0.201 0.930 0.824
Low MEE vs High MEE 3 0.375 0.994 0.927
Intermediate MEE vs High MEE 2 0.195 0.942 0.767

[TableWrap ID: pone-0088102-t003] doi: 10.1371/journal.pone.0088102.t003.
Table 3  Metabolites Difference of patients in different-MEE groups.
No Metabolite Selected Chemical shift Group
1 LDL 0.87(br),1.26–1.29(br) CH3-(CH2)n-
2 VLDL 0.88–0.90(br),1.30–1.31(br) CH3-(CH2)n-
3 Valine 0.98–0.99(d) γ-CH3
4 3-Hydroxybutyrate 1.19–1.20(d) -CH3
5 Lactate 1.32–1.34(d) -CH3
6 Alanine 1.46–1.48(d) -CH3
7 N-Acetyl glycoprotein 2.04(s)
8 Glutamine 2.09(m) β-CH2
4.29(t) α-CH
2.29(m) γ-CH2
9 Methionine 2.14(s) S-CH3
10 Acetone 2.22–2.23(s) -CH3
11 Succinate 2.42(s) -CH2
12 Creatine 3.03(s) -CH3
13 Choline 3.21(s) -CH3
14 Phosphocholine 3.22(s) -CH3
15 β-Glucose 3.24–3.25(dd) C-H2
3.40–3.41(t) C-H4
3.45–3.46(m) C-H5
3.47–3.48(t) C-H3
3.71–3.72(m),3.88–3.90(dd) C-H6
16 α-Glucose 3.55(s) C-H2
3.69–3.70(t) C-H3
3.73–3.75(m) C-H6
3.83(m) C-H5&6
17 Trimethylamine-N-oxide 3.26(s) -CH3
18 Glycine 3.97(s) -CH2

S: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; br: broad peak.

[TableWrap ID: pone-0088102-t004] doi: 10.1371/journal.pone.0088102.t004.
Table 4  Different metabolite levels of patients in different-MEE groups.
Metabolite Low MEE Intermediate MEE High MEE P-value
(n = 15) (n = 31) (n = 15)
LDL 136.4±89.4 93.4±46.8 89.1±63.6 NS
VLDL 119.9±78.8 85.0±43.7 80.6±51.0 NS
Valine 56.8±10.5 48.4±11.8# 47.9±9.3 0.036
3-Hydroxybutyrate 12.1±11.3 35.5±38.6 61.7±84.6# 0.032
Lactate 436.0±143.7 481.1±171.6 483.0±113.1 NS
Alanine 102.1±18.9 82.9±29.0 60.5±28.8#† -<0.001
N-Acetyl glycoprotein 81.7±19.2 79.0±12.3 73.0±10.8 NS
Glutamine 91.9±25.3 73.3±18.3# 70.4±15.8# 0.006
Methionine 55.8±13.5 43.9±15.2# 34.1±15.7# 0.001
Acetone 12.6±11.2 47.0±59.3 65.7±78.5# 0.044
Succinate 7.7±4.2 18.2±9.9# 26.4±17.3# -<0.001
Creatine 17.1±5.9 23.2±10.3# 18.0±5.0 0.036
Choline 52.8±16.9 45.4±10.2 44.6±10.4 NS
Phosphocholine 101.2±20.0 98.7±21.8 97.2±19.8 NS
β-Glucose 241.9±50.1 245.0±43.6 254.5±39.7 NS
α-Glucose 95.1±16.2 87.1±20.0 79.6±15.4 NS
Trimethylamine-N-oxide 111.8±16.5 125.0±43.5 127.7±40.6 NS
Glycine 83.6±22.8 90.4±36.3 69.6±37.7 NS

#vs. low MEE, P<0.05; vs media MEE, P<0.05.

Article Categories:
  • Research Article
Article Categories:
  • Biology
    • Biochemistry
      • Chemical Biology
      • Small Molecules
Article Categories:
  • Chemistry
    • Analytical Chemistry
      • Chemical Analysis
Article Categories:
  • Medicine
    • Cardiovascular
      • Heart Failure
    • Clinical Research Design
      • Case-Control Studies
    • Diagnostic Medicine
      • Pathology
        • General Pathology
          • Biomarkers
    • Radiology
      • Diagnostic Radiology
        • Echocardiography

Previous Document:  Distinct Domains within the Human Cytomegalovirus UL26 Protein Are Important for Wildtype Viral Repl...
Next Document:  Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on C-Reactive Protein, Interleukin 6 and Tu...